Personalized, bio-engineered, dermo-epidermal skin grafts. CUTISS is a Swiss clinical-stage life sciences company focussed on regenerative medicine and skin tissue engineering. It is developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries. The lead product denovoSkin promises to take skin surgery to the next level and revolutionize current treatments. It is a bio-engineered and personalized dermo-epidermal human skin graft, currently in Phase IIb clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA. CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft. The company’s knowledge in skin bio-engineering and biology offers several growth opportunities in regenerative medicine. Established in 2017, the company is a spin-off from University of Zurich (UZH) / University Children’s Hospital. It successfully exited the Wyss Zurich accelerator in 2022. Headquartered at the Bio-Technopark in Zurich, it won the Top 100 Swiss Startup Award 2020, and has raised over CHF 55 million from private investors, family offices and public bodies.